Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 2/20 | 0.38 |
| ▸ | CTSG | P08311 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | PLG | P00747 | 1/20 | 0.38 |
| ▸ | CMA1 | P23946 | 1/20 | 0.38 |
| ▸ | CTRC | Q99895 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | GSK3A | P49840 | 2/20 | 0.36 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3625933 | 0.81 | EP300 (0.46) | EP300TACR1KMT2AMEN1ELANE | |
| SCHEMBL25800349 | 0.65 | ALDH1A1 (0.53) | EP300KMT2AMEN1ELANECTSG | |
| SCHEMBL5300149 | 0.65 | ROCK1 (0.56) | GAASMN1; SMN2 | |
| SCHEMBL31226135 | 0.62 | TACR1 (0.55) | EP300TACR1KMT2AMEN1ELANE | |
| SCHEMBL16775234 | 0.61 | KMT2A (0.70) | EP300KMT2AMEN1ELANECTSG | |
| SCHEMBL16759895 | 0.61 | KMT2A (0.70) | EP300KMT2AMEN1ELANECTSG | |
| SCHEMBL9438388 | 0.61 | PARP1 (0.48) | KMT2AMEN1ALDH1A1GAAGSK3B | |
| SCHEMBL14577578 | 0.61 | CHRM5 (0.59) | KMT2AMEN1ALDH1A1CHRM5 | |
| SCHEMBL18306073 | 0.60 | MEN1 (0.49) | EP300KMT2AMEN1ELANECTSG | |
| SCHEMBL28155521 | 0.60 | ELANE (0.47) | EP300TACR1KMT2AMEN1ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069385-A1 | Antidiabetic Oxazolidinediones and Thiazolidinediones | MERCK SHARP & DOHME CORP. | 2009-03-12 | — | — | US | disclosed |
| US-20090069385-A1 | Antidiabetic Oxazolidinediones and Thiazolidinediones | MERCK SHARP & DOHME CORP. | 2009-03-12 | — | — | US | disclosed |
| EP-1909789-A2 | ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES | Merck & Co., Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1909789-A2 | ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES | Merck & Co., Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007018956-A3 | ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES | MERCK & CO INC (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007018956-A2 | ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES | MERCK & CO., INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007018956-A2 | ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES | MERCK & CO., INC. (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069385-A1 | Antidiabetic Oxazolidinediones and Thiazolidinediones | PPARD, PPARA, PPARG | EP300 1262/4885TACR1 2644/4885KMT2A 1608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.